Filing Flows › CytomX Therapeutics (CTMX) › Q3 2026
CytomX Therapeutics (CTMX) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
CytomX Therapeutics (CTMX) reported revenue of $1.7M for the third quarter 2026 (Q3 2026), -72% from a year earlier and +19% from the quarter before.
CytomX Therapeutics, Q3 2026: revenue $1.7M (-72% year over year), net loss $20.0M, operating cash flow $16.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.7M | +19% | -72% |
| Operating profit | −$23.5M | — | — |
| Net earnings | −$20.0M | — | — |
| Operating cash flow | $16.6M | — | — |
| Free cash flow | $16.1M | — | — |
What changed
Revenue was $1.7M in Q3 2026, down 72% year over year and up 19% from the previous quarter.
Operating costs exceeded revenue by $23.5M, an operating margin of -1392.3%. Total costs grew 16% against a revenue fall of 72%. The fastest-growing cost line was General & admin (+36%). The quarter ended with a net loss of $20.0M, narrower than the previous quarter's $20.7M loss.
Operating cash flow was $16.6M. Non-cash charges added back $2.8M of share-based compensation. Working capital and other items added $33.8M. Capital expenditures of $589K left free cash flow of $16.1M.
Questions
What was CytomX Therapeutics' revenue in the third quarter 2026?
CytomX Therapeutics (CTMX) reported revenue of $1.7M for the third quarter 2026 (Q3 2026), -72% from a year earlier and +19% from the quarter before.